Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Nov 30;18(5):2085470.
doi: 10.1080/21645515.2022.2085470. Epub 2022 Jun 8.

Reply letter to "Immunogenicity and safety of a quadrivalent high-dose inactivated influenza vaccine compared with a standard-dose quadrivalent influenza vaccine in healthy people aged 60 years or older: a randomized Phase III trial"

Sanjay Hadigal  1 , Laura Colombo  2 , Scott Haughie  3
Affiliations
Comment

Reply letter to "Immunogenicity and safety of a quadrivalent high-dose inactivated influenza vaccine compared with a standard-dose quadrivalent influenza vaccine in healthy people aged 60 years or older: a randomized Phase III trial"

Sanjay Hadigal et al. Hum Vaccin Immunother. .

Abstract

A recent study reported that the high-dose quadrivalent influenza vaccine provided superior immunogenicity and efficacy versus the standard-dose quadrivalent vaccine in the elderly. However, we need to view these results in terms of public health benefits as well. The Number Needed to Vaccinate (NNV) is an important tool to measure the benefit of a given vaccine. Further, NNV evaluates the benefits of a vaccine in preventing and controlling communicable diseases. Considering the target of vaccination and coverage of 75% not met in the elderly in Europe, it is important not to prioritize one vaccine over the other, but rather to increase the vaccine coverage with all the available vaccines.

Keywords: Number needed to vaccinate; at-risk group prioritization; flu; high-dose quadrivalent vaccine; influenza vaccine; standard-dose quadrivalent vaccine; vaccine coverage; vaccine shortage.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest was reported by the author(s).

Comment on

References

    1. Pepin S, Nicolas JF, Szymanski H, Leroux-Roels I, Schaum T, Bonten M, Icardi G, Shrestha A, Tabar C.. QHD00011 study team. Immunogenicity and safety of a quadrivalent high-dose inactivated influenza vaccine compared with a standard-dose quadrivalent influenza vaccine in healthy people aged 60 years or older: a randomized Phase III trial. Hum Vaccines Immunother. 2021. ;17(12):1–3. Epub 2021 Oct 29. PMID: 34714720; PMCID: PMC8903946. doi: 10.1080/21645515.2021.1983387. - DOI - PMC - PubMed
    1. DiazGranados CA, Dunning AJ, Kimmel M, Kirby D, Treanor J, Collins A, Pollak R, Christoff J, Earl J, Landolfi V, et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med. 2014. ;371(7):635–645. PMID: 25119609. doi: 10.1056/NEJMoa1315727. - DOI - PubMed
    1. Van Tilbeurgh M, Lemdani K, Beignon AS, Chapon C, Tchitchek N, Cheraitia L, Marcos Lopez E, Pascal Q, Le Grand R, Maisonnasse P, et al. Predictive markers of immunogenicity and efficacy for human vaccines. Vaccines (Basel). 2021. ;9(6):579. PMID: 34205932; PMCID: PMC8226531. doi: 10.3390/vaccines9060579. - DOI - PMC - PubMed
    1. Olliaro P, Torreele E, Vaillant M. COVID-19 vaccine efficacy and effectiveness-the elephant (not) in the room. Lancet Microbe. 2021. ;2(7):e279–e280. Epub 2021 Apr 20. PMID: 33899038; PMCID: PMC8057721. doi: 10.1016/S2666-5247(21)00069-0. - DOI - PMC - PubMed
    1. Ranganathan P, Pramesh CS, Aggarwal R. Common pitfalls in statistical analysis: absolute risk reduction, relative risk reduction, and number needed to treat. Perspect Clin Res. 2016. ;7(1):51–53. PMID: 26952180; PMCID: PMC4763519. doi: 10.4103/2229-3485.173773. - DOI - PMC - PubMed